Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early alzheimeŕs disease

Current Alzheimer Research

Volumn 8, Issue 8, 2011, Pages 853-859

  Straten, Guido ^a   Saur, Ralf ^a   Laske, Christoph ^a   Gasser, Thomas ^b   Annas, Peter ^c   Basun, Hans ^c   Leyhe, Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer's disease; GDNF; Lithium; Neuroprotection; Neurotrophic effect; Placebo controlled trial

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LITHIUM SULFATE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HALLUCINATION; HUMAN; LITHIUM BLOOD LEVEL; MALE; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; MULTICENTER STUDY; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIMANIC AGENTS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; SINGLE-BLIND METHOD; SULFATES;

EID: 82055176904     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511798192754     Document Type: Article

References (53)

1. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 20: 101-113 (2003).
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. CD005593 (2006).
3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. CD003154 (2006).
4. Chuang D-M, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 62: 4-6 (2007).
5. Engel T, Goni-Oliver P, Gómez de Barreda E, Lucas JJ, Hernández F, Avila J. Lithium, a potential protective drug in Alzheimer's Disease. Neurodegener Dis 5: 247-249 (2008).
6. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459 (1996).
7. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102: 6990-6995 (2005).
8. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439 (2003).
9. Tajes M, Gutierrez-Cuesta J, Folch J, Ferrer I, Caballero B, Smith MA, et al. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol 67: 612-623 (2008).
10. Fukumoto T., Morinobu S, Okamato Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158: 100-106 (2001).
11. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang, D-M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43: 1173-1179 (2002).
12. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41: 387-394 (2007).
13. Leyhe T, Stransky E, Eschweiler G, Buchkremer G, Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 258: 124-128 (2008).
14. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761 (2008).
15. Williams LR, Inouye G, Cummins V, Pelleymounter MA. Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: doseresponse comparison to nerve growth factor and brain-derived neurotrophic factor. J Pharmacol Exp Ther 277: 1140-1151 (1996).
16. Weis C, Marksteiner J, Humpel C. Nerve growth factor and glial cell line-derived neurotrophic factor restore the cholinergic neuronal phenotype in organotypic brain slices of the basal nucleus of Meynert. Neuroscience 102: 129-138 (2001).
17. Straten, G, Eschweiler, GW, Maetzler, W, Laske, C, Leyhe, T. GDNF concentrations in CSF and serum of patients with early Alzheimeŕs disease and normal controls. J Alzheimers Dis 18(2): 331-337 (2009).
18. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132 (1993).
19. Straten G, Schmeer C, Kretz A, Gerhardt E, Kügler S, Schulz JB, et al. Potential synergistic protection of retinal ganglion cells from axotomyinduced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X- chromosome-linked inhibitor of apoptosis. Neurobiol Dis 11: 123-133 (2002).
20. Kao CH, Chen SH, Chio CC, Chang CK, Lin MT. Exogenous administration of glial cell line-derived neurotrophic factor im proves recovery after spinal cord injury. Resuscitation 77: 395-400 (2008).
21. Opacka-Juffry J, Ashworth S, Hume SP, Martin D, Brooks DJ. Blunt SB. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport: 7: 348-352 (1995).
22. Moore MW, Klein RD, Farĩnas I, Sauer H, Armanini M, Phillips H, et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382: 76-79 (1996).
23. Rosenthal A. The GDNF protein family: gene ablation studies reveal what they really do and how. Neuron 22: 201-203 (1999).
24. Oatley JM, Brinster RL. Regulation of spermatogonial stem cell self-renewal in mammals. Annu Rev Cell Dev Biol 24: 263-286 (2008).
25. Suzuki H, Hase A, Miyata Y, Arahata K, Akazawa C. Prominent expression of glial cell line-derived neurotrophic factor in human skeletal muscle. J Comp Neurol 402: 303-312 (1998).
26. Martinelli PM, Camargos ER, Morel G, Tavares CA, Nagib PR, Machado CR. Rat heart GDNF: effect of chemical sympathectomy. Histochem Cell Biol 118: 337-343 (2002).
27. Orth SR, Ritz E, Suter-Crazzolara C. Glial cell line derived neurotrophic factor (GDNF) is expressed in the human kidney and is a growth factor for human mesangial cells. Nephrol Dial Transplant 15: 589-595 (2000).
28. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, et al. Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83 (1996).
29. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381: 785-789 (1996).
30. Yano H, Chao MV. Neurotrophin receptor structure and interactions. Pharm Acta Helv 74: 253-260 (2000).
31. Du Y, Li X, Yang D, Zhang X, Chen S, Huang K, et al. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp Biol Med 233: 881-890 (2008).
32. Li Z, Wang B, Wu X, Cheng SY, Paraoan L, Zhou J. Identification, expression and functional characterization of the GRAL gene. J Neurochem 95: 361-376 (2005).
33. Trupp M, Belluardo N, Funakoshi H, Ibánez CF. Complementary and overlapping expression of glial cell line derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 17: 3554-3567 (1997).
34. Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi I, Kozuru T, et al. Decreased levels of whole blood glial cell linederived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 9(5): 607-612 (2006).
35. Michel TM, Frangou S, Camara S, Thiemeyer D, Jecel J, Tatschner T, et al. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. Eur Psychiatry 23(6): 413-420 (2008).
36. Otsuki K, Uchida S, Watanuki T, Wakabayashi Y, Fujimoto M, Matsubara T, et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 42(14): 1145-1153 (2008).
37. Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA. Lithium treatment alters brain concentrations of nerve growth factor, brainderived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6(3): 225-231 (2003).
38. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16(3): 649-656 (2009).
39. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, et al. Lithium trial in Alzheimer's disease: a randomized, singleblind, placebo-controlled, multicenter 10- week study. J Clin Psychiatry 70(6): 922-931 (2009).
40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944(1984).
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, D.C: American Psychiatric Press (1994).
42. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
43. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-1364 (1984).
44. Okragly AJ, Haak-Frendscho M. An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp Neurol 145: 592-596 (1997).
45. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39(9): 1159-1165 (1989).
46. Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegrí C, Vilaplana J, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 15: 333-344 (2009).
47. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, et al. Greater cortical gray matter density in lithiumtreated patients with bipolar disorders. Biol Psychiatry 52: 7-16 (2007).
48. Yucel K, McKinnon MC, Taylor VH, Macdonald K, Alda M, Young LT, et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal study. Psychopharmacology 195: 357-367 (2007).
49. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 19: 20-22 (2005).
50. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359-360 (2007).
51. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30: 1125-1128 (2006).
52. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord 12: 87-94 (2010).
53. Kessing LV, Søndergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 65(11): 1331-1335 (2008).